Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
A promising medication could slow brain tumors in children.
2.
Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.
3.
Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers
4.
AI catches one-third of interval breast cancers missed at screening
5.
AI tool identifies women at high risk of interval breast cancer
1.
Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment
2.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
3.
Glycopyrrolate: The Secret Weapon for Excessive Sweating
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
5.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation